RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles, the world’s largest biopharmaceutical services company, has
been named to FORTUNE magazine’s “World’s Most Admired Companies” list
for 2015.
Quintiles CEO Tom Pike (Photo: Business Wire)
Quintiles is ranked third overall in FORTUNE’s Healthcare: Pharmacy
and Other Services category with the top ranking for the reputation
attribute of “global competitiveness” and second within the segment for
its “people management.”
FORTUNE's World's Most Admired Companies list is the definitive report
card on corporate reputations. Since 1997, Fortune has identified,
selected and ranked the World’s
Most Admired Companies, uncovering the business practices that make
these companies highly regarded among their peers.
“I would like to congratulate Quintiles’ employees around the world for
making this possible,” said Quintiles Chief Executive Officer Tom Pike.
“Being named one of the World’s Most Admired Companies is a significant
milestone in the history of our company.
“It is recognition that Quintiles is headed in the right direction to
deliver value for customers as we improve their probability of success,”
Pike continued. “It is now up to all of us in the organization to live
up to these expectations.”
Quintiles recently entered its 33rd year of operation, having been
established at the University of North Carolina at Chapel Hill in 1982
by biostatistics professors Dr. Dennis Gillings, CBE and Gary Koch, PhD.
The company, which once operated out of a trailer on the UNC campus, now
conducts business in approximately 100 countries.
More than three decades later, Quintiles is the world’s largest provider
of biopharmaceutical development and commercial outsourcing services as
the company helped develop or commercialize all of 2013’s top-100
best-selling drugs on the market (2014 statistics pending).
During 2014, Quintiles was recognized as the “Best Contract Research
Organization” (CRO) in the UK SCRIP awards, named “Asia CRO of the Year”
by Frost and Sullivan, voted “Best CRO in Asia” in the BioPharma Asia
Industry Awards and was named “Best Contract Sales Organization (CSO)”
in the PharmaField awards as well as being named to the Fortune 500 for
the first time.
Most Admired Methodology
The survey employed by FORTUNE to designate its “World’s Most Admired
Companies” list assesses nine reputation drivers considered to be
crucial to a company’s global success including financial soundness,
long-term investment value, people management, social responsibility,
use of assets, quality of management, quality of products/services,
innovation and global competitiveness.
These attributes were developed prior to the inception of the Most
Admired Companies rankings in the mid-1980s through a series of
interviews with executives and industry analysts to determine the
qualities that make a company worthy of admiration.
Raters are asked to evaluate each eligible company on attributes by
assigning a score from zero ('Poor') to ten ('Excellent'). For the
purposes of the industry rankings, a company’s overall score is
determined through a simple average of the individual attribute scores.
Companies who rank in the top half of their industry are defined as
“most admired” within their industry.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest
provider of biopharmaceutical development and commercial outsourcing
services. With a network of more than 32,000 employees conducting
business in approximately 100 countries, we helped develop or
commercialize all of 2013’s top-100 best-selling drugs on the market.
Quintiles applies the breadth and depth of our service offerings along
with extensive therapeutic, scientific and analytics expertise to help
our customers navigate an increasingly complex healthcare environment as
they seek to improve efficiency and effectiveness in the delivery of
better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here
to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150219005907/en/
Source: Quintiles